Centenary Nobel Prize in Physiology or Medicine for the cell cycle

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of molecular medicine

• Publication date

  2001-09-22

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00109-001-0297-zPMID 11862313
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sponsorship, authorship, and accountability.

  2001cited by this paper
• Linking molecular and bedside research: designing a clinical research infrastructure

  2001cited by this paper
• Antisense oligonucleotides: promise and reality.

  2001cited by this paper
• Clinical investigators--the endangered species revisited.

  2001cited by this paper
• Gene delivery from a DNA controlled-release stent in porcine coronary arteries

  2000cited by this paper
• Novel non-endocytic delivery of antisense oligonucleotides.

  2000cited by this paper
• RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts

  2000cited by this paper
• Antisense oligodeoxynucleotide and ribozyme design.

  2000cited by this paper
• Design of nuclease resistant protein kinase calpha DNA enzymes with potential therapeutic application.

  2000cited by this paper
• Metal ions in ribozyme folding and catalysis.

  2000cited by this paper
• Ribozyme structures and mechanisms.

  2000cited by this paper
• Selecting optimal antisense reagents.

  2000cited by this paper
• Novel Negative Regulatory Element in the Platelet-derived Growth Factor B Chain Promoter That Mediates ERK-dependent Transcriptional Repression*

  2000cited by this paper
• Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase.

  2000cited by this paper
• Ribozyme Oligonucleotides Against Transforming Growth Factor-&bgr; Inhibited Neointimal Formation After Vascular Injury in Rat Model: Potential Application of Ribozyme Strategy to Treat Cardiovascular Disease

  2000cited by this paper
• The delivery of antisense therapeutics.

  2000cited by this paper
• In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis.

  2000cited by this paper
• Adenovirus-Mediated Expression of a Ribozyme to c-mybmRNA Inhibits Smooth Muscle Cell Proliferation and Neointima Formation In Vivo

  1999cited by this paper
• Inhibition of bcr-abl Oncogene Expression by Novel Deoxyribozymes (DNAzymes)

  1999cited by this paper
• CTAB‐mediated enrichment for active forms of novel dimeric maxizymes

  1999cited by this paper
• New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury

  1999cited by this paper
• Selectivity of polyamines on the stability of RNA-DNA hybrids containing phosphodiester and phosphorothioate oligodeoxyribonucleotides.

  1999cited by this paper
• Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome.

  1999cited by this paper
• Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function.

  1999cited by this paper
• New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury

  1999cited by this paper
• Suppression of Smooth Muscle Cell Proliferation by a c-myc RNA-cleaving Deoxyribozyme*

  1999cited by this paper
• Function and biological applications of catalytic nucleic acids.

  1999cited by this paper
• Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a porcine coronary model.

  1999cited by this paper
• An Antisense Oligonucleotide Primer

  1999cited by this paper
• Inhibition of infection of incoming HIV‐1 virus by RNA‐cleaving DNA enzyme

  1999cited by this paper
• Sequence‐specific cleavage of Huntingtin mRNA by catalytic DNA

  1999cited by this paper
• Antisense Pharmacodynamics: Critical Issues in the Transport and Delivery of Antisense Oligonucleotides

  1999cited by this paper
• A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability.

  1999cited by this paper
• Structure, folding and catalysis of the small nucleolytic ribozymes.

  1999cited by this paper
• Specificity of novel allosterically trans‐ and cis‐activated connected maxizymes that are designed to suppress BCR‐ABL expression

  1999cited by this paper
• Targeted cleavage of HIV‐1 envelope gene by a DNA enzyme and inhibition of HIV‐1 envelope‐CD4 mediated cell fusion

  1998cited by this paper
• Human gene therapy.

  1998cited by this paper
• Mechanism and utility of an RNA-cleaving DNA enzyme.

  1998cited by this paper
• Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs (review).

  1998cited by this paper
• Signal transduction in arteriosclerosis: mechanical stress-activated MAP kinases in vascular smooth muscle cells (review).

  1998cited by this paper
• Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis (review).

  1998cited by this paper
• Effects of helical structures formed by the binding arms of DNAzymes and their substrates on catalytic activity.

  1998cited by this paper
• Recent developments in the hammerhead ribozyme field.

  1998cited by this paper
• Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease

  1998cited by this paper
• Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease.

  1998cited by this paper
• Extravasation of macromolecules.

  1998cited by this paper
• Role of AP-1 complex in angiotensin II-mediated transforming growth factor-beta expression and growth of smooth muscle cells: using decoy approach against AP-1 binding site.

  1998cited by this paper
• Oligonucleotide-Based Gene Therapy for Cardiovascular Disease

  1998cited by this paper
• Sequence specific cleavage of the HIV‐1 coreceptor CCR5 gene by a hammer‐head ribozyme and a DNA‐enzyme: inhibition of the coreceptor function by DNA‐enzyme

  1998cited by this paper
• Early growth response factor 1: a pleiotropic mediator of inducible gene expression

  1998cited by this paper
• Hammerhead ribozyme design and application

  1998cited by this paper
• DNA-enhanced peroxidase activity of a DNA-aptamer-hemin complex.

  1998cited by this paper
• The clinical investigator: bewitched, bothered, and bewildered--but still beloved.

  1997cited by this paper
• Gene therapy - promises, problems and prospects

  1997cited by this paper
• Identification and characterization of second-generation antisense oligonucleotides.

  1997cited by this paper
• When Checkpoints Fail Review

  1997cited by this paper
• The role of the general clinical research center in promoting patient-oriented research into the mechanisms of disease

  1997cited by this paper
• Withholding research results in academic life science. Evidence from a national survey of faculty.

  1997cited by this paper
• Therapeutic potential and mechanism of action of oligonucleotides and ribozymes.

  1997cited by this paper
• In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction

  1997cited by this paper
• Effect of phosphorothioated oligonucleotides on neointima formation in the rat carotid artery. Dissecting the mechanism of action.

  1997cited by this paper
• The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty.

  1997cited by this paper
• A minimised hammerhead ribozyme with activity against interleukin-2 in human cells.

  1997cited by this paper
• A general purpose RNA-cleaving DNA enzyme.

  1997cited by this paper
• Characterization and divalent metal-ion dependence of in vitro selected deoxyribozymes which cleave DNA/RNA chimeric oligonucleotides.

  1997cited by this paper
• Stormy weather for clinical research in Germany and the United States.

  1997cited by this paper
• Antisense oligonucleotide to proto-oncogene c-myb inhibits the formation of intimal hyperplasia in experimental vein grafts.

  1997cited by this paper
• Local delivery of c-myb antisense oligonucleotides during balloon angioplasty.

  1997cited by this paper
• Cell cycle regulation and control of angioplasty restenosis

  1997cited by this paper
• Correlation of Activity with Stability of Chemically Modified Ribozymes in Nuclei Suspension

  1996cited by this paper
• A catalytic DNA for porphyrin metallation

  1996cited by this paper
• Sequence-independent inhibition of in vitro vascular smooth muscle cell proliferation, migration, and in vivo neointimal formation by phosphorothioate oligodeoxynucleotides.

  1996cited by this paper
• Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes.

  1996cited by this paper
• Dependence on Mg2+ ions of the activities of dimeric hammerhead minizymes

  1996cited by this paper
• Porphyrin metalation catalyzed by a small RNA molecule

  1996cited by this paper
• Catalytic activities of hammerhead ribozymes with a triterpenoid linker instead of stem/loop II

  1996cited by this paper
• HAMMERHEAD MINIZYMES WITH HIGH CLEAVAGE ACTIVITY : A DIMERIC STRUCTURE AS THE ACTIVE CONFORMATION OF MINIZYMES

  1996cited by this paper
• Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA.

  1996cited by this paper
• A comparison of the in vitro activity of DNA-armed and all-RNA hammerhead ribozymes.

  1995cited by this paper
• Antisense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries.

  1995cited by this paper
• In vitro activity of minimised hammerhead ribozymes.

  1995cited by this paper
• Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix (*)

  1995cited by this paper
• Chemical Modification of Hammerhead Ribozymes

  1995cited by this paper
• Restenosis after coronary angioplasty.

  1995cited by this paper
• The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism.

  1995cited by this paper
• Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury.

  1995cited by this paper
• A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.

  1995cited by this paper
• Polyamine effects on purine-purine-pyrimidine triple helix formation by phosphodiester and phosphorothioate oligodeoxyribonucleotides.

  1995cited by this paper
• High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates.

  1994cited by this paper
• Transcatheter Delivery of c‐myc Antisense Oligomers Reduces Neointimal Formation in a Porcine Model of Coronary Artery Balloon Injury

  1994cited by this paper
• Expanding the scope of RNA catalysis.

  1994cited by this paper
• In vivo decay kinetic parameters of hammerhead ribozymes.

  1994cited by this paper
• Using linkers to investigate the spatial separation of the conserved nucleotides A9 and G12 in the hammerhead ribozyme.

  1994cited by this paper
• Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.

  1994cited by this paper
• A DNA enzyme that cleaves RNA.

  1994cited by this paper
• Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia.

  1993cited by this paper
• Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

  1993cited by this paper
• Inhibition of phorbol ester-induced cellular adhesion by competitive binding of NF-kappa B in vivo

  1993cited by this paper
• Hammerhead ribozymes: importance of stem-loop II for activity.

  1993cited by this paper
• Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages.

  1993cited by this paper

• Molecular and Immunomodulatory Actions of New Antiasthmatic Agents: Exploring the Diversity of Biologics in Th2 Endotype Asthma.

  2022cites this paper
• Mathematical and computer simulation of the electrophysical properties of a multicellular structure exposed to nanosecond electrical pulses

  2021cites this paper
• State-of-the-art and future perspectives of functional polymers

  2019cites this paper
• New Targeted Therapies for Uncontrolled Asthma.

  2019cites this paper
• Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities.

  2018cites this paper
• A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial

  2018cites this paper
• Modulating microRNAs in cardiac surgery patients: Novel therapeutic opportunities?

  2017cites this paper
• Nanomaterials for delivery of nucleic acid to the central nervous system (CNS).

  2017cites this paper
• Use of Biomaterials and Biomolecules for the Prevention of Restenosis

  2015cites this paper
• Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.

  2015cites this paper
• Interventional Pharmacology: Stent-Based Drug Delivery, Local Drug Delivery Management of Patients Before and After PCI

  2014cites this paper
• Recent advances in drug eluting stents.

  2013cites this paper
• Targeted delivery of siRNA into breast cancer cells via phage fusion proteins.

  2013cites this paper
• Biomaterials and bioengineering tomorrow’s healthcare

  2013cites this paper
• Chapter 46 – Cardiac Gene Therapy

  2012cites this paper
• Efficient synthesis of 2'-C-α-aminomethyl-2'-deoxynucleosides.

  2012cites this paper
• Cardiac gene therapy.

  2010cites this paper
• Significance of Controlling Chronic Proliferative Cholangitis in the Treatment of Hepatolithiasis

  2009cites this paper
• Oral Delivery of Nucleic Acid Drugs

  2009cites this paper
• Natural Functional Nucleic Acids: Ribozymes and Riboswitches

  2009cites this paper
• Angiotensin II induction of PDGF-C expression is mediated by AT1 receptor-dependent Egr-1 transactivation

  2008cites this paper
• Advances in Gene-Based Therapy for Heart Failure

  2008cites this paper
• Syntheses of (2')3'-15N-amino-(2')3'-deoxyguanosine and determination of their pKa values by 15N NMR spectroscopy.

  2007cites this paper
• Gene therapy in the treatment of heart failure.

  2007cites this paper
• Cell-based GATA4 cardiac gene transfer using cell-penetrating peptide.

  2007cites this paper
• Nano-Carriers of Drugs and Genes for the Treatment of Restenosis

  2007cites this paper
• Gene therapy for restenosis: biological solution to a biological problem.

  2007cites this paper
• Improved synthesis of 2'-amino-2'-deoxyguanosine and its phosphoramidite.

  2006cites this paper
• Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes

  2006cites this paper
• Zn2+-dependent deoxyribozymes that form natural and unnatural RNA linkages.

  2005cites this paper
• Inhibition of Viral Replication by Ribozyme: Mutational Analysis of the Site and Mechanism of Antiviral Activity

  2005cites this paper
• Oligonucleotide-Based Therapeutic Options against Hepatitis C Virus Infection

  2005cites this paper
• Vascular smooth muscle cell proliferation is dependent upon upregulation of mitochondrial transcription factor A (mtTFA) expression in injured rat carotid artery.

  2005cites this paper
• Treatment of in-stent restenosis.

  2005cites this paper
• CLEA I AGE VERSATILITY OF 8-17 DEOXYRIBOZYME DINUCLEOTIDE JUNCTION CLEAVAGE VERSATILITY OF 8-17 DEOXYRIBOZYME By

  2004cites this paper
• Natural and engineered nucleic acids as tools to explore biology

  2004cites this paper
• Treatment of Vulnerable Plaques: Current and Future Strategies

  2004cites this paper
• Novel approaches to therapy

  2004cites this paper
• Cardiovascular Gene Therapy: Angiogenesis and Beyond

  2004cites this paper
• Biological Bypass in Cardiovascular Surgery

  2004cites this paper
• Tracing sequence diversity change of RNA-cleaving deoxyribozymes under increasing selection pressure during in vitro selection.

  2004cites this paper
• Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo

  2004cites this paper
• Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents.

  2004cites this paper
• CD4 Expression Decrease by Antisense Oligonucleotides: Inhibition of Rat T CD4+ Cell Reactivity

  2003cites this paper
• Magnetofection--a highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo.

  2003cites this paper
• Deoxyribozymes with 2'-5' RNA ligase activity.

  2003cites this paper
• Beyond angioplasty: novel developments in interventional cardiology

  2002cites this paper